Skip to content
Screener

Rein Therapeutics Inc. RNTX Total Revenue

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Gilead Sciences logo
Gilead SciencesGILD
$7.8B+10.2%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
CTO
Citius Oncology, Inc.CTOR
$1.49M—
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$29.11M-2.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$64.86M+224%

Other financials

Income statement

See full
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-—
Free cash flow-$6.3M—

Valuation

See full
Market cap$60.57M+119%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0×0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by Rein Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Rein Therapeutics Inc.’s 10-Q, filed May 15, 2026. Open the filing →

Filed
May 15, 2026, 7:56 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-225352

FAQ

What is Rein Therapeutics Inc.'s total revenue?
Rein Therapeutics Inc. (RNTX) reported total revenue of $0 in Q1 2026.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Rein Therapeutics Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude